Abbott’s Interferon-free Hep C Combo With Ribavirin Has High Cure Rates
This article was originally published in The Pink Sheet Daily
Abbott revealed more data from its Phase II Aviator program Nov. 10 during a press conference at the American Association for the Study of Liver Disease meeting showing high cure rates in some difficult patient populations and a 100% cure rate for the easier to treat genotype 1 subgroup.
You may also be interested in...
Abbott’s proprietary pharmaceutical business will officially begin business as a separate entity called AbbVie Jan. 1, but a key pipeline opportunity – bardoxolone – is in doubt after a Phase III trial was terminated due to safety.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.